Source link : https://www.newshealth.biz/health-news/adding-palbociclib-to-standard-care-improved-pfs-in-triple-positive-breast-cancer/
Findings from the phase III PATINA trial, presented at the San Antonio Breast Cancer Symposium, showed that adding the CDK4/6 inhibitor palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy significantly extended progression-free survival (PFS) by nearly 15 months in patients with hormone receptor-positive, HER2-positive metastatic breast cancer. In this exclusive MedPage Today video, Gaia […]
Author : News Health
Publish date : 2025-01-17 18:08:53
Copyright for syndicated content belongs to the linked Source.